InflaRx (IFRX) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Key product updates and differentiation

• Izicopan, an oral C5aR antagonist, shows higher bioavailability, faster onset, and lower CYP3A4 inhibition compared to avacopan, suggesting improved safety and efficacy profiles.

• No hepatotoxicity observed in approximately 200 patients treated with izicopan, even at high doses, supporting a clean safety profile.

• Izicopan’s rapid achievement of steady-state plasma levels allows for lower dosing and potentially better patient outcomes.

• The molecule’s lower risk of drug-drug interactions is attributed to significantly reduced CYP3A4 inhibition.

• If avacopan is withdrawn from the market, izicopan could quickly capitalize on the opportunity due to its differentiated profile.

Clinical development and trial results

• Proof-of-concept studies in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) showed encouraging efficacy signals, especially in reducing draining tunnels and pain in HS.

• Four-week basket study in HS demonstrated responses comparable or superior to other phase II/III HS trials, despite being non-placebo-controlled.

• Long-term toxicology data now supports indefinite dosing, enabling progression to phase IIB trials.

• Additional PK simulations and regulatory discussions are ongoing to finalize dosing and trial design for the next phase.

• Phase IIB study is required before moving to pivotal trials in HS.

Strategic focus and pipeline outlook

• HS remains the primary focus, but CSU is also under consideration for further development, especially in severe patient subsets.

• Expansion into other autoimmune indications is possible, with future updates expected at the upcoming Capital Markets Day.

• Commercial differentiation in HS will rely on biologic-like efficacy, safety, and unique benefits such as draining tunnel reduction.

• Regulatory discussions are ongoing to define endpoints that reflect clinical benefits beyond standard HiSCR measures.

• Partnerships may be pursued to expand into additional indications, depending on resources.